Eurofins Scientific Acquires 70,000 of Its Own Shares for 4.7 Million Euros
Eurofins Scientific purchased 70,000 of its own shares between January 5 and January 9, 2026, for a total amount of 4.7 million euros, according to the company's statement. The weighted average price was 67.5971 euros per share.
The transaction took place over five consecutive trading days, the company reports. On January 5, Eurofins acquired 29,926 shares at an average price of 65.9433 euros on Euronext Paris, and 74 shares at 65.0200 euros on the CEUX platform. The following sessions involved volumes of 10,000 shares each, exclusively on the Paris market. Average prices gradually increased over the days, from 68.1028 euros on January 6 to 69.5790 euros on January 9. This progression reflects the evolution of prices during the period, without the group commenting on this trend.
Regulatory Compliance and Transparency
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The disclosure of these transactions complies with the obligations set forth in Article 5(1)(b) of European Regulation No. 596/2014 concerning market abuse, the statement specifies. Eurofins Scientific provides the complete details of each individual transaction on its investor website, under the section dedicated to share buyback programs. The financial instrument involved bears the identification code FR0014000MR3, while the issuer is identified under the LEI code 529900JEHFM47DYY3S57. The group has not communicated the specific objectives of this buyback program or the prospects for the use of these self-held shares.
Purpose of the Share Buybacks
The statement does not provide any information on the purpose of these share buybacks. Eurofins Scientific has not indicated whether these shares are intended to be cancelled, allocated as part of employee share ownership plans, used for external growth operations, or retained to stabilize the share price. The total amount invested is approximately 4.72 million euros according to the data provided.
SectorSanté · Vaccins et laboratoires de recherche›Services médicaux
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Contexte
Period
Period: 1T2026
Key reported figures
Revenue: 1789M€
Guidance from the release
Eurofins a rencontré des vents contraires importants et temporaires.
Malgré une croissance organique modérée, la rentabilité et les marges progressent.
Risks mentioned
Baisse de la demande en raison de conditions climatiques défavorables en Amérique du Nord.
Rationalisation des contrats dans les diagnostics cliniques en Espagne et en Italie.
Opportunities identified
Lancement de nouveaux contrats renforçant notre portefeuille BioPharma.
Initiatives de digitalisation et amélioration du réseau de laboratoires.
Les informations présentées dans cet article sont fournies à titre purement indicatif et ne constituent en aucun cas une recommandation d'investissement, une incitation à acheter ou vendre un actif financier, ni un conseil en placement. Le lecteur est invité à réaliser ses propres recherches avant toute décision.
Les investissements en bourse comportent des risques, notamment de perte en capital. La performance passée d'un actif ou d'un marché ne présage en rien de ses performances futures. Toute décision d'investissement doit être prise en tenant compte de votre situation financière personnelle, de vos objectifs et de votre tolérance au risque.